Organization | GRUPPO ITALIANO TERAPIE INNOVATIVE NEI LINFOMI

GRUPPO ITALIANO TERAPIE INNOVATIVE NEI LINFOMI Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial

2008

NCT00795613

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2008

Timeline

NOW

Now

Alternative names

GITIL (GRUPPO ITALIANO TERAPIE INNOVATIVE NEI LINFOMI)

Active Ingredients

Drugs in Phase 2 Trials (8)

bleomycin (blenoxane) (1 trial)

cyclophosphamide (cytoxan) (1 trial)

dacarbazine (dtic-dome) (1 trial)

doxorubicin (Doxil) (1 trial)

etoposide (vepesid) (1 trial)

procarbazine (matulane) (1 trial)

vinblastine (velban) (1 trial)

vincristine (oncovin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Hodgkin Disease (Phase 2)

Lymphoma (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 1
# of Trial APIs: 8